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The transferrin receptor (TfR) interacts with two pro-
teins important for iron metabolism, transferrin (Tf)
and HFE, the protein mutated in hereditary hemochro-
matosis. A second receptor for Tf, TfR2, was recently
identified and found to be functional for iron uptake in
transfected cells (Kawabata, H., Germain, R. S., Vuong,
P. T., Nakamaki, T., Said, J. W., and Koeffler, H. P. (2000)
J. Biol. Chem. 275, 16618–16625). TfR2 has a pattern of
expression and regulation that is distinct from TfR, and
mutations in TfR2 have been recognized as the cause of
a non-HFE linked form of hemochromatosis (Cam-
aschella, C., Roetto, A., Cali, A., De Gobbi, M., Garozzo,
G., Carella, M., Majorano, N., Totaro, A., and Gasparini,
P. (2000) Nat. Genet. 25, 14–15). To investigate the rela-
tionship between TfR, TfR2, Tf, and HFE, we performed
a series of binding experiments using soluble forms of
these proteins. We find no detectable binding between
TfR2 and HFE by co-immunoprecipitation or using a
surface plasmon resonance-based assay. The affinity of
TfR2 for iron-loaded Tf was determined to be 27 nM,
25-fold lower than the affinity of TfR for Tf. These re-
sults imply that HFE regulates Tf-mediated iron uptake
only from the classical TfR and that TfR2 does not com-
pete for HFE binding in cells expressing both forms of
TfR.
Mammalian organisms possess complex mechanisms to reg-
ulate the absorption and uptake of iron on both the cellular and
organism level. The transferrin receptor (TfR)1 plays a central
role in iron metabolism in which transferrin (Tf)-bound iron is
taken up into cells via binding to TfR and endocytosis of the
TfRzTf complex (reviewed in Ref. 1). TfR is a homodimeric
membrane glycoprotein that binds two molecules of Tf (1).
Upon exposure to the acidic pH of the endosome, iron is re-
leased from Tf and enters a chelatable intracellular pool from
which it is utilized for the metabolic needs of the cell or incor-
porated into the storage protein ferritin. Iron-free Tf (apoTf)
remains bound to TfR at the low pH value of the acidic vesicle
(#pH 6.4), and the apoTfzTfR complex is then recycled to the
cell surface where apoTf dissociates at the higher pH value of
blood (;pH 7.4).
In cell lines and in tissues such as the intestine and placenta,
TfR associates with HFE, another protein involved in the reg-
ulation of iron metabolism (2, 3), and HFE association with TfR
has been shown to negatively regulate Tf-mediated iron uptake
in transfected cells (4–6). HFE is a class I major histocompat-
ibility complex (MHC)-related protein that is mutated in pa-
tients with hereditary hemochromatosis (7), an iron storage
disease characterized by excessive iron absorption leading to
an accumulation of iron principally in the liver, heart, pan-
creas, and parathyroid and pituitary glands (8). Like class I
MHC molecules, HFE is composed of a heavy chain with three
extracellular domains (a1, a2, and a3), a single transmem-
brane-spanning region, a short cytoplasmic domain, and the
non-covalently associated light chain, b2-microglobulin. Class I
MHC proteins bind peptides in a groove within the a1-a2
superdomain and present them to T cells as part of the adapt-
ive immune response against pathogens (9). HFE contains a
narrowed version of the class I peptide binding groove and does
not bind peptides or play any known role in the immune system
(10). Instead HFE associates with TfR (2, 3) in a pH-dependent
interaction, such that a nanomolar binding affinity is observed
at pH 7.5 with no detectable binding at pH 6 and below (10).
Crystal structures of HFE (10), TfR (11), and the HFEzTfR
complex (12) reveal the molecular basis for the interaction
between TfR and HFE and, when combined with biochemical
studies, suggest a binding site on TfR for Tf (13).
Recently, a second receptor for Tf, TfR2, was identified (14).
Like TfR, it is a type II transmembrane protein consisting of an
N-terminal cytoplasmic domain and a large C-terminal ectodo-
main. Human TfR2 shares 45% amino acid sequence identity in
its extracellular region with human TfR. In human and mouse,
TfR2 is highly expressed in the liver and in peripheral blood
mononuclear cells (15, 16). In contrast to TfR, expression of
TfR2 is not down-regulated as a result of iron overload, con-
sistent with the absence of iron-responsive elements in the 39
untranslated sequence of TfR2 mRNA (16). Flow cytometric
analyses of Tf binding to TfR2 expressed in a Chinese hamster
ovary cell line lacking endogenous TfR demonstrate that TfR2
binds Tf (14). In addition, expression of TfR2 in this cell line
permits cell growth in iron-chelated media, demonstrating that
TfR2 is functional for Tf-mediated iron uptake (15). A homozy-
gous nonsense mutation in TfR2 has been identified as the
cause of a form of hemochromatosis that is not linked to mu-
tations in HFE (17), demonstrating that TfR2 is critical for
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maintenance of iron homeostasis, but possible interactions be-
tween TfR2 and HFE were not investigated.
In this communication, we compared the interactions of the
ectodomains of TfR2 and TfR with Tf and HFE. We find that Tf
binds to TfR2, although more weakly than it binds TfR, but
that TfR2 does not interact detectably with HFE. These data
imply that HFE exerts its influence on iron homeostasis
through interactions with TfR and not TfR2.
EXPERIMENTAL PROCEDURES
Expression and Purification of TfR2—A soluble version of human
TfR2 was expressed in a lytic baculovirus/insect cell expression system
using the approach described previously for expression of soluble TfR
(10). A construct encoding residues 133–801 (the C-terminal amino acid
of wild-type TfR2) was joined 39 to a gene segment encoding the leader
peptide from the baculovirus protein GP67, a 6xHis-tag, and a factor Xa
cleavage site in a modified form of the pAcGP67A expression vector
(Pharmingen). Recombinant virus was generated by co-transfection of
the transfer vector with linearized viral DNA (Baculogold; Pharmin-
gen). TfR2 was purified from supernatants of baculovirus-infected High
5 cells using nickel-nitrilotriacetic acid chromatography (Ni-NTA Su-
perflow; Qiagen) followed by gel filtration chromatography using a
Superdex-200 fast protein liquid chromatography column (Amersham
Pharmacia Biotech). The gel filtration step was required to remove
aggregated TfR2 that eluted in the void volume of the column and that
did not bind Tf. Unaggregated TfR2 eluted in a broad peak at a higher
apparent molecular weight than did TfR (data not shown). N-terminal
sequencing of purified TfR2 yielded the sequence ADPHHHHHHSS-
GIEGRGEFGRLYW, which corresponds to the 6xHis-tag, spacer, factor
Xa site, and residues 133–137 of TfR2.
Determination of Protein Concentrations—Protein concentrations
were determined spectrophotometrically using extinction coefficients at
280 nm of 83360 M21 cm21 (Tf), 96570 M21 cm21 (HFE), 93790 M21 cm21
(TfR), and 93430 M21 cm21 (TfR2). Extinction coefficients were calcu-
lated as described previously (10).
Biosensor Assays—A BIACORE 2000 biosensor system (Biacore AB)
was used to assay the interaction of TfR and TfR2 with HFE and human
Tf (Sigma). Tf was further purified by gel filtration chromatography
prior to biosensor analyses. The BIACORE system includes a biosensor
chip with a dextran-coated gold surface to which one protein (referred to
as the “ligand”) is immobilized. Binding of an injected protein (the
“analyte”) to the immobilized protein results in changes in surface
plasmon resonance that are directly proportional to the amount of
bound protein and read out in real time as resonance units (RU) (18,
19). TfR or TfR2 was immobilized using an oriented coupling procedure
in which an anti-His-tag antibody (anti-pentahis; Qiagen) was co-
valently attached to the chip surface followed by injection of the His-
tagged protein. The anti-His-tag antibody was coupled (2000–3000 RU)
to all four flow cells on a CM5 biosensor chip (Biacore AB) using
standard primary amine-coupling chemistry (BIACORE manual). His-
tagged TfR or TfR2 was then injected in 50 mM PIPES, pH 7.5, 150 mM
NaCl, 0.005% surfactant P20 and allowed to bind to individual flow
cells at levels between 200 and 400 RU. Although a small portion of the
bound TfR or TfR2 dissociates within a few minutes of this binding step,
the majority remains bound, and the baseline does not drift signifi-
cantly. A flow cell containing only immobilized antibody served as a
blank. HFE or Tf was injected over the TfR- or TfR2-coupled flow cells
at room temperature in 50 mM PIPES, pH 7.5, 150 mM NaCl, 0.005%
surfactant P20. Equilibrium dissociation constants (KD) were calcu-
lated from association and dissociation rate constants, which were
derived from binding experiments with 4-min association and 4-min
dissociation phases using a flow rate of 50 ml/min. Kinetic constants
were calculated from sensorgram data using simultaneous fitting of the
association and dissociation phases with global fitting to all curves in
the working set using CLAMP 99 (20). The data were fit to a bivalent
ligand model, i.e, the two sequential binding steps shown in Equation 1.
Tf 1 TfR2 -|0
ka1
kd1
TfzTfR2 KD15
kd1
ka1
Tf1TfzTfR2 -|0
ka2
kd2
TfzTfR2zTf KD25
kd2
ka2
(Eq. 1)
Coimmunoprecipitation of HFE with TfR and TfR2—HFE (450 pmol)
and TfR (150 pmol) or TfR2 (150 pmol) were incubated for 30 min at
room temperature in 20 ml of 20 mM Tris-Cl, 150 mM NaCl, pH 7.5.
Either 2 mg of anti-pentahis antibody (Qiagen) or 2 mg anti-HFE (1C3)
(10) antibody were added to the sample as indicated, followed by 30 ml
of protein G-Sepharose (Amersham Pharmacia Biotech). The mixture
was incubated on a rotating platform for 1 h at room temperature.
Samples were layered on top of 1 ml of 20 mM Tris-Cl, 150 mM NaCl, pH
7.5, 15% sucrose and pelleted in a microfuge for 2 min at 14000 3 g. The
supernatants were aspirated, and the pellets were resuspended in 23
Laemmli buffer. The samples were heated to 95 °C for 3 min, loaded
onto an SDS polyacrylamide (10%) gel, and electrophoresed under de-
naturing and reducing conditions. The experiment was repeated three
times with similar results.
RESULTS
Biosensor Assays Using Soluble TfR and TfR2—To investi-
gate the binding properties of TfR2, we expressed a soluble,
polyhistidine-tagged form of the TfR2 ectodomain (residues
133–801) and performed a series of affinity measurements
using a surface plasmon resonance-based assay. Purified solu-
ble TfR2 was attached to the sensor chip through an anti-His-
tagged antibody, and a series of injections of Tf and HFE were
performed at pH 7.5. Kinetic analysis of Tf binding to TfR2
(Fig. 1A) yielded two affinities, KD1 5 27 nM and KD2 5 350 nM,
when the data were fit to a model with stepwise binding of two
molecules of Tf to each TfR2 homodimer. Under identical con-
ditions the corresponding Tf affinities for TfR (Fig. 1A) are KD1
5 1.1 nM and KD2 5 29 nM, similar to results obtained from
previous biosensor- and cell-based measurements of the affin-
ity between TfR and Tf (1, 10). Hence, the affinity of the first Tf
binding to TfR2 is about 25-fold lower than the corresponding
affinity of Tf for TfR. This is in agreement with cell surface
measurements of the Tf affinity for full-length TfR and TfR2, in
which a 30-fold difference was observed (15).
FIG. 1. Biosensor analyses of Tf and HFE binding to immobi-
lized TfR and TfR2. A, sensorgrams (colored curves) of injected Tf
binding to TfR2 (left panel) or TfR (right panel) immobilized using a
covalently attached anti-His-tagged antibody. Best fit binding curves
(assuming a bivalent ligand model) are shown as thin black lines. B,
sensorgrams showing injection of 10 mM HFE and 5 mM Tf onto flow cells
containing either TfR2 (red) and TfR (blue). Injection duration for HFE
and Tf are indicated above the sensorgrams.
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We next examined the ability of TfR2 to bind HFE, using TfR
as a positive control. The affinity of soluble HFE for immobi-
lized TfR is ;300 nM (10), and binding can be observed at
concentrations as low as 20 nM. However, for TfR2, injections of
HFE at concentrations up to 10 mM did not lead to detectable
binding (Fig. 1B), implying a KD .. 10 mM. These HFE injec-
tions were performed on TfR2 samples that were competent to
bind Tf and under conditions in which HFE binding to TfR was
easily observed (Fig. 1B). We previously demonstrated that a
KD . 9 mM derived from the interaction of a soluble mutant
HFE with soluble TfR is insufficient to confer an interaction in
the cell between membrane-bound forms of these proteins (21).
We therefore assume that binding between membrane HFE
and TfR2 is unlikely, even when both proteins are tethered to
the same membrane.
Immunoprecipitations—As independent verification of the
biosensor analysis demonstrating that HFE and TfR2 do not
interact, we also tested whether TfR2 could be coimmunopre-
cipitated with HFE using an anti-HFE monoclonal antibody.
As shown in Fig. 2, TfR, but not TfR2, coimmunoprecipitates
with HFE. These experiments were done at an HFE concentra-
tion of 9 mM, implying the KD for the TfR2-HFE interaction is
higher than 9 mM.
DISCUSSION
Here we report the expression and characterization of a
soluble version of TfR2 analogous to soluble TfR, whose inter-
actions with Tf and HFE were previously described (10). Using
a quantitative biosensor-based assay, we find that the affinity
of Tf for soluble TfR2 is ;25-fold lower than that for TfR. Both
biosensor and immunoprecipitation experiments fail to detect
any interaction between the ectodomains of HFE and TfR2,
implying a KD .. 10 mM, which should be insufficient to confer
an interaction between membrane-bound forms of the mole-
cules (21).
The TfR structural features that are involved in binding
HFE have been determined from a crystallographic structure of
the HFEzTfR complex at 2.8-Å resolution (12). The structure
shows that two helices in the helical domain of TfR (helical
domain helices 1 and 3) (Fig. 3) interact with the HFE a1 and
a2 domain helices, forming an extensive interface. The inter-
face includes both apolar and polar interactions and buries
1000 Å2 of solvent-accessible surface area per subunit. About
half of the TfR residues that form contacts with HFE are
replaced by different amino acids in TfR2 (see Fig. 3 and Table
I), suggesting a structural interpretation for the lack of HFE
binding by TfR2. Although some critical binding residues are
identical (e.g. TfR Leu-619) or conservatively replaced (e.g. TfR
Val-622 versus TfR2 Ile-654), some substitutions in TfR2 are
likely to be incompatible with HFE binding. For example, sev-
eral replacements significantly reduce the buried surface area
in the interface (e.g. TfR Arg-623 versus TfR2 Gly-655). Several
FIG. 2. HFE does not immunoprecipitate with TfR2. Coomassie
blue-stained SDS polyacrylamide (10%) gel of immunoprecipitation of
HFE in the presence of TfR or TfR2 is shown. HFE was incubated with
TfR or TfR2 at pH 7.5 for 30 min at room temperature. Immunopre-
cipitations were performed with either the anti-pentahis antibody or an
anti-HFE antibody. The mobilities of TfR2, TfR, HFE, and the antibody
heavy chains (hc) and light chains (lc) are denoted in the right-hand
margin. The HFE light chain, b2-microglobulin, is present on gels
composed of a higher percentage of acrylamide (data not shown). The
experiment was repeated three times with similar results.
FIG. 3. TfR2 amino acid substitutions in the HFE-binding site
mapped onto TfR structure. Ribbon diagram of one polypeptide
chain of the TfR homodimer derived from the 2.8-Å HFEzTfR complex
structure (12) shown with the two helices that interact with HFE
highlighted in green (helical domain helices 1 and 3). TfR residues that
are involved in binding HFE and substituted in TfR2 are shown in red.
TABLE I
HFE-interacting residues on TfR and their counterparts in TfR2
HFE-interacting residues on TfR were identified from the 2.8-Å res-
olution HFEzTfR complex structure as described (12). Corresponding
residues in TfR2 are listed based on the sequence alignment in Ref. 14
with differences indicated in bold lettering. The number of hydrogen
bonds (in parentheses) and % accessible surface area were calculated
using the protein-protein interactions server (24). % Accessible surface
area, percent of total interface area contributed by each TfR residue;
vdW, interactions with HFE involving only van der Waals interactions;
H bond, interactions with HFE that include hydrogen bonds.
TfR residue TfR2 residue % Accessiblewith HFE
Type of
interaction
Ser-616 Asp-648 3 vdW
Leu-619 Leu-651 10 vdW
Val-622 Ile-654 2 vdW
Arg-623 Gly-655 7 vdW
Asn-626 Asn-656 5 vdW
Arg-629 Ser-661 10 H bonds (4)
Gln-640 Gln-672 10 H bond (1)
Trp-641 Trp-673 5 vdW
Tyr-643 Tyr-675 4 vdW
Ser-644 Ser-676 4 vdW
Arg-646 Arg-678 5 vdW
Asp-648 Asp-680 1 H bond (1)
Phe-650 Ile-682 7 vdW
Arg-651 Arg-683 5 vdW
Ser-654 Glu-686 5 vdW
Thr-657 Arg-689 4 vdW
Thr-658 Gln-690 4 H bond (1)
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other substitutions replace small polar residues (serine or thre-
onine) with charged residues (e.g. TfR Ser-654 versus TfR2
Glu-686). Other substitutions would disrupt the hydrogen bond
network in the interface (e.g. TfR Arg-629 versus TfR2 Ser-
661). These changes in TfR2 would be expected to destabilize
the interaction with HFE.
TfR2 and TfR can both bind Tf, suggesting that they share a
similar Tf-binding site. There is no crystal structure for a
TfzTfR complex; however some features of the Tf-binding site in
TfR can be inferred from biochemical studies and knowledge of
the structures of TfR (11) and the TfRzHFE complex (12). Com-
petition studies demonstrate that HFE and Tf bind to an over-
lapping site on TfR (13); therefore some of the HFE-interacting
residues in TfR must also contribute to the Tf-binding site
(Table I). In support of this idea, site-directed mutagenesis has
shown that TfR residues 646–648, which are present at the
HFE-binding site, are critical for Tf binding (22). Residues
646–648 are conserved in TfR2 and are therefore likely to be
involved in the TfR2 interaction with Tf (Table I). Similarly,
other HFE-interacting residues that are conserved between
TfR2 and TfR may contribute to the Tf-binding site.
HFE competes with Tf for binding to TfR (13) and reduces
cellular iron levels in cells expressing both HFE and TfR (4–6,
21, 23). Here we demonstrate that HFE does not bind to TfR2
and thus would not be expected to regulate TfR2-mediated iron
uptake. Curiously, for both HFE and TfR2, the mechanism
whereby mutation of either protein leads to hemochromatosis
remains unclear. How does the absence of HFE and subsequent
increased cellular iron absorption by TfR on the basolateral
side of the intestinal crypt cell lead to increased iron transport
across the enterocyte? In addition, how does the absence of
TfR2 in liver and erythroid cells cause intestinal cells to sense
iron deficiency despite the body’s state of iron overload? These
questions remain to be answered, but the recent finding that
TfR2 is mutated in a non-HFE-related form of hemochromato-
sis (17) implies that TfR2 must be included in any models for
the regulation of iron homeostasis. Our demonstration that
HFE does not bind to TfR2 implies that TfR2 cannot compete
for HFE binding in cells expressing both forms of TfR and is
consistent with the emerging picture that TfR and TfR2 are
regulated in distinct ways.
Acknowledgments—We thank Dr. Peter Snow of the Caltech Protein
Expression Facility for construction of recombinant baculovirus ex-
pressing TfR2 and Dr. Andrew Herr for help with biosensor analyses.
REFERENCES
1. Richardson, D. R., and Ponka, P. (1997) Biochim. Biophys. Acta 1331, 1–40
2. Feder, J. N., Penny, D. M., Irrinki, A., Lee, V. K., Lebro´n, J. A., Watson, N.,
Tsuchihashi, Z., Sigal, E., Bjorkman, P. J., and Schatzman, R. C. (1998)
Proc. Natl. Acad. Sci. U. S. A. 95, 1472–1477
3. Parkkila, S., Waheed, A., Britton, R. S., Bacon, B. R., Zhou, X. Y., Tomatsu, S.,
Fleming, R. E., and Sly, W. S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94,
13198–13202
4. Gross, C. N., Irrinki, A., Feder, J. N., and Enns, C. A. (1998) J. Biol. Chem.
273, 22068–22074
5. Roy, C. N., Penny, D. M., Feder, J. N., and Enns, C. A. (1999) J. Biol. Chem.
274, 9022–9028
6. Corsi, B., Levi, S., Cozzi, A., Corti, A., Altimare, D., Albertini, A., and Arosio,
P. (1999) FEBS Lett. 460, 149–152
7. Feder, J. N., Gnirke, A., Thomas, W., Zsuchihashi, Z., Ruddy, D. A., Basava, A.,
Dormishian, F., Domingo, R., Ellis, M. C., Fullan, A., Hinton, L. M., Jones,
N. L., Kimmel, B. E., Kronmal, G. S., Lauer, P., Lee, V. K., Loeb, D. B.,
Mapa, F. A., McCelland, E., Meyer, N. C., Mintier, G. A., Moeller, N., Moore,
T., Morikang, E., Prass, C. E., Quintana, L., Starnes, S. M., Schatzman,
R. C., Brunke, K. J., Drayna, D. T., Risch, N. J., Bacon, B. R., and Wolff,
R. K. (1996) Nat. Genet. 13, 399–408
8. Cullen, L. M., Anderson, G. J., Ramm, G. A., Jazwinska, E. C., and Powell,
L. W. (1999) Annu. Rev. Med. 50, 87–98
9. Garcia, K. C., Teyton, L., and Wilson, I. A. (1999) Annu. Rev. Immunol. 17,
369–397
10. Lebro´n, J. A., Bennett, M. J., Vaughn, D. E., Chirino, A. J., Snow, P. M.,
Mintier, G. A., Feder, J. N., and Bjorkman, P. J. (1998) Cell 93, 111–123
11. Lawrence, C. M., Ray, S., Babyonyshev, M., Galluser, R., Borhani, D. W., and
Harrison, S. C. (1999) Science 286, 779–782
12. Bennett, M. J., Lebro´n, J. A., and Bjorkman, P. J. (2000) Nature 403, 46–53
13. Lebro´n, J. A., West, A. P., and Bjorkman, P. J. (1999) J. Mol. Biol. 294,
239–245
14. Kawabata, H., Yang, R., Hirama, T., Vuong, P. T., Kawno, S., Gombart, A. F.,
and Koeffler, H. P. (1999) J. Biol. Chem. 274, 20826–20832
15. Kawabata, H., Germain, R. S., Vuong, P. T., Nakamaki, T., Said, J. W., and
Koeffler, H. P. (2000) J. Biol. Chem. 275, 16618–16625
16. Fleming, R. E., Migas, M. C., Holden, C. C., Waheed, A., Britton, R. S.,
Tomatsu, S., Bacon, B. R., and Sly, W. S. (2000) Proc. Natl. Acad. Sci.
U. S. A. 97, 2214–2219
17. Camaschella, C., Roetto, A., Cali, A., De Gobbi, M., Garozzo, G., Carella, M.,
Majorano, N., Totaro, A., and Gasparini, P. (2000) Nat. Genet. 25, 14–15
18. Fa¨gerstam, L. G., Frostell-Karlsson, A., Karlsson, R., Persson, B., and
Ro¨nnber, I. (1992) J. Chromatogr. 597, 397–410
19. Malmqvist, M. (1993) Nature 361, 186–187
20. Morton, T. A., and Myszka, D. G. (1998) Methods Enzymol. 295, 268–294
21. Ramalingam, T. S., West, A. P., Lebro´n, J. A., Nangiana, J. S., Hogan, T. H.,
Enns, C. A., and Bjorkman, P. J. (2000) Nat. Cell Biol., in press
22. Dubljevic, V., Sali, A., and Goding, A. (1999) Biochem. J. 341, 11–14
23. Riedel, H. D., Muckenthaler, M. U., Gehrke, S. G., Mohr, I., Brennan, K.,
Herrmann, T., Fitscher, B. A., Hentze, M. W., and Stremmel, W. (1999)
Blood 94, 3915–3921
24. Jones, S., and Thornton, J. M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 13–20
TfR2 Binding Properties38138
